Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Change in Accured Expenses (2016 - 2026)

Champions Oncology has reported Change in Accured Expenses over the past 17 years, most recently at $1.2 million for Q1 2026.

  • For Q1 2026, Change in Accured Expenses rose 3515.62% year-over-year to $1.2 million; the TTM value through Jan 2026 reached $1.1 million, up 761.96%, while the annual FY2025 figure was $395000.0, 462.39% up from the prior year.
  • Change in Accured Expenses for Q1 2026 was $1.2 million at Champions Oncology, up from $388000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $1.2 million in Q1 2026 and troughed at -$755000.0 in Q3 2025.
  • A 5-year average of $84352.9 and a median of $137000.0 in 2024 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 3140.0% in 2022 and later skyrocketed 3515.62% in 2026.
  • Year by year, Change in Accured Expenses stood at -$287000.0 in 2022, then skyrocketed by 76.66% to -$67000.0 in 2023, then surged by 304.48% to $137000.0 in 2024, then skyrocketed by 183.21% to $388000.0 in 2025, then soared by 198.2% to $1.2 million in 2026.
  • Business Quant data shows Change in Accured Expenses for CSBR at $1.2 million in Q1 2026, $388000.0 in Q4 2025, and -$755000.0 in Q3 2025.